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Abstract
Background: New approaches are required to address the needs of complex undiagnosed diseases patients. These
approaches include clinical genomic diagnostic pipelines, utilizing intra- and multi-disciplinary platforms, as well as
specialty-specific genomic clinics. Both are advancing diagnostic rates. However, complementary cross-disciplinary
approaches are also critical to address those patients with multisystem disorders who traverse the bounds of
multiple specialties and remain undiagnosed despite existing intra-specialty and genomic-focused approaches.
The diagnostic possibilities of undiagnosed diseases include genetic and non-genetic conditions. The focus on
genetic diseases addresses some of these disorders, however a cross-disciplinary approach is needed that also
simultaneously addresses other disorder types. Herein, we describe the initiation and summary outcomes of a
public health system approach for complex undiagnosed patients - the Undiagnosed Diseases Program-Western
Australia (UDP-WA).
Results: Briefly the UDP-WA is: i) one of a complementary suite of approaches that is being delivered within health
service, and with community engagement, to address the needs of those with severe undiagnosed diseases; ii)
delivered within a public health system to support equitable access to health care, including for those from remote
and regional areas; iii) providing diagnoses and improved patient care; iv) delivering a platform for in-service and
real time genomic and phenomic education for clinicians that traverses a diverse range of specialties; v) retaining
and recapturing clinical expertise; vi) supporting the education of junior and more senior medical staff; vii) designed
to integrate with clinical translational research; and viii) is supporting greater connectedness for patients, families
and medical staff.
(Continued on next page)
* Correspondence: Gareth.baynam@health.wa.gov.au
1Genetic Services of Western Australia, Department of Health, Government of
Western Australia, Perth, WA, Australia
2School of Paediatrics and Child Health, University of Western Australia,
Perth, WA, Australia
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Baynam et al. Orphanet Journal of Rare Diseases  (2017) 12:83 
DOI 10.1186/s13023-017-0619-z
(Continued from previous page)
Conclusion: The UDP-WA has been initiated in the public health system to complement existing clinical genomic
approaches; it has been targeted to those with a specific diagnostic need, and initiated by redirecting existing
clinical and financial resources. The UDP-WA supports the provision of equitable and sustainable diagnostics and
simultaneously supports capacity building in clinical care and translational research, for those with undiagnosed,
typically rare, conditions.
Keywords: Diagnosis, Genomics, Phenomics, Undiagnosed, Diagnostic odyssey, Clinical best practice, Policy,
Precision public health
Background
Undiagnosed diseases are often rare, sometimes extremely
rare. These conditions may represent expanded pheno-
types of more frequent rare disorders; also sometimes
apparently single diseases may be the phenotypic expres-
sion of multiple disorders or an unusual presentation of a
more common disease [1]. They may also be due to an
underlying truly new disease. In each of these instances
the primary aetiology can be genetic or not (e.g., epigen-
etic or environmental). There are 5,000–8,000 known rare
diseases and, because of their individual rarity, achieving a
diagnosis can be particularly challenging. In a European
study, 25% of individuals waited 5–30 years for a diagnosis
and in 40% of instances the initial diagnosis was wrong
[2]. Similar findings were demonstrated in Australia; ap-
proximately 30% of patients waited for more than 5 years
to receive a diagnosis, a similar number saw more than 6
doctors before receiving a diagnosis, and half had at least
one incorrect diagnosis [3]. Reflecting a priority for the
global rare diseases community, local and international ef-
forts [4–6] have been developed to address this diagnostic
odyssey, since an accurate diagnosis is the bedrock of best
practice medical care.
Most rare diseases have genetic origins. Hence, techno-
logical advances such as chromosomal microarray, followed
in more recent years by the clinical application of massively
parallel sequencing (primarily exomic sequencing), have
resulted in a markedly increased diagnostic yield in rare
diseases [7]. International experience with the clinical im-
plementation of exome sequencing has typically shown a
diagnostic yield of 25–30%, whereas prior to the use of this
technology the yield in some cases was less than 10% [5].
The implementation of additional technological advances
such as whole genome sequencing and phenotype-enabled
diagnostic analyses [8] will further increase the diagnostic
yield, but even so it is likely that at least 50% of patients for
whom a diagnosis is sought using these technologies will
remain undiagnosed. This means that complementary ap-
proaches to “solve the unsolved” are required.
The United States (US) National Institutes of Health
(NIH) Undiagnosed Diseases Program (UDP) commenced
in 2008 to address the unmet needs of those living with
rare or multisystem diseases who remained undiagnosed
after exhaustive efforts. For most pediatric patients in the
program, the diagnostic odyssey averaged more than
5 years. The UDP had three major objectives: i) to provide
an accurate diagnosis ii) to facilitate new disease discovery,
and iii) to improve understanding of biological pathways
that would lead to a greater understanding of human
physiology in rare and more common disorders [1]. The
volume of undiagnosed patients applying to participate in
the program was overwhelming and underscored the
magnitude of the unmet need.
Technological advances in genomics, and other –
omics, are key enablers of the UDP. However the most
important factor is the involvement of multiple rare dis-
eases experts, largely through consultations during UDP
admissions [1]. In the UDP, approximately half of the
diagnoses were made directly from disease agnostic, but
phenotype informed, genomic testing through massively
parallel sequencing. The remaining diagnoses were made
by focused biochemical, radiologic, and molecular studies
suggested by rare disease experts given the opportunity to
investigate the problem as a collaborative team. The UDP
has a core power of focusing assessments and expertise in
one place at one time and centered on one patient at a
time; it harnesses the richness of face-to-face discussion
and real-time and in-person clinical assessments.
The UDP paradigm and nexus expanded to an extra-
mural network of nodes at leading clinical academic
centers in the US, i.e., the Undiagnosed Diseases
Network (UDN) [9]. Subsequently, the Undiagnosed
Diseases Network International (UDNI), an expanding
international network operating under the same core
principles, was formed [4]. The set up of UDNI was
preceded by a number of formative meetings in Europe
(Italy, Budapest and Vienna) and Japan (Tokyo) and a
workshop in Perth, Western Australia [4]. The Perth
workshop aimed to identify the key success factors and
challenges to implementing a UDP in Australia as a
means to find diagnostic solutions for intensive users of
clinical services.
Following the Perth workshop, the UDP-WA was con-
ceived and implemented as a program within the public
health system in March 2016, with links to research
partners but not driven from academia. In Western
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Australia, the public health system is comprised of a
Department of Health and four Area Health Services.
The Department of Health acts as the system manager
and commissions, monitors and evaluates the perform-
ance of services provided by the Area Health Services.
The public health system can be accessed and used by
all residents in Western Australia.
The vision was that the UDP-WA would also support
other Australian states and New Zealand to establish
UDPs as part of the UDNI. Herein we describe the
implementation and initial learnings of the UDP-WA.
Methods
The first UDNI meeting in Italy sought to share the
benefits of the UDP and the UDN and enhance them
through partnering internationally. The workshop was
sponsored by the US NIH Common Fund and a patient
organization, the Wilhelm Foundation, who along with
the NIH recognised the importance of international col-
laborative efforts in tackling undiagnosed diseases. It was
primarily attended by European nationals, and included
several Australian delegates.
Less than 1 year later, in August 2015, Western
Australia hosted the first Australasian UDP workshop.
This was attended by a largely Australian audience,
with a strong local (Western Australian) presence. All
Australian jurisdictions (with the exception of the
Northern Territory and Tasmania) were represented at
the workshop. Importantly, a number of Asian govern-
ment and research agencies also attended (primarily
from Singapore and Malaysia). In all, close to 90 re-
searchers, clinicians, patient groups and representatives
of public and private organizations attended.
Workshop attendees heard from founders of the NIH
program about running a UDP. Through facilitated
discussions, considerable time during the workshop was
dedicated to exploring what difference a UDP program in
Australia or regional countries would make to patients,
clinicians and health systems. The challenges and benefits
of implementing a UDP were also explored. Ultimately,
the recognised benefits motivated attendees and ensured
support for the commencement of the UDP in WA.
Recognition of these benefits also fostered a strong
interest in the UDP model elsewhere in Australia, and
helped strengthen a national network of clinicians and
researchers working in the area of rare diseases.
A range of challenges that implementing a UDP could
present were discussed in this Workshop. Notable among
the issues raised was the difficulty posed by operationaliz-
ing a UDP within a public health system as a clinical entity
using existing resources. This issue is compounded as the
health system model has a significant focus on individual
specialties and health services which can complicate their
interaction. This in turn raised the challenge of capturing
the broad range of clinical knowledge required to enable
the program to work; an integral function of a UDP. Other
key concerns were questions on how the program could
be provided equitably such as reaching patients in regional
WA, and also how it could be sustainable. Many of the in-
novative ways in which these challenges have been met
are described within this paper.
The workshop also comprehensively explored the
positives a UDP could bring. An immense volume of
potential positive outcomes attendees thought could
accrue from delivering a UDP were raised. Three broad
areas of benefit were distilled from the conversations
being’improved health system outcomes’, ‘improved pa-
tient outcomes and ‘enhanced knowledge sharing infor-
mation’. Within each of these broad areas a range of
potential benefits was identified. For example, within:
(i) improved health system outcomes: increased effi-
ciency through reduced duplication of testing, reduced
waitlists, better referral pathways, and better treatment;
better allocation and coordination of resources that has
greater alignment with patient need. (ii) improved pa-
tient outcomes: for those diagnosed through the pro-
gram, diagnosis could lead to earlier treatment and
appropriate management and reduced stress associated
with not knowing condition. For those remaining with-
out a diagnosis a sense of closure for the patient and
their family. (iii) enhanced knowledge sharing informa-
tion: for diagnosed families the ability to inform other
family members of the condition and the genetic
(where relevant) implications for them; for UDP clini-
cians, greater connection, collaboration and coordin-
ation with other clinicians.
Building on the momentum and discussion outcomes
of the workshop, local clinical geneticists and policy-
makers employed within the Western Australian public
health system championed the idea of a UDP in West-
ern Australia. They initiated intensive engagement and
relationship building with clinicians at Western Austra-
lia’s children’s hospital to promote the development of
a UDP. Heads of clinical specialty departments were
initially approached for support, which they gave in
principle. Higher executive-level support from the
hospital and Department of Health was then obtained.
Following this, clinicians within the clinical specialty
departments were approached to participate in the pro-
gram as part of a cross-disciplinary team. Support from
these clinicians (some of whom are also Department
Heads) represents an enormous generosity in the form
of donated time, since delivery of the UDP-WA has
occurred within existing budgets. Some departments
nominated one clinician and others created a roster to
share the experience. Still others rearranged their pri-
vate clinics to participate in this program delivered
within the public health system.
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Results
In November 2015, the Department of Health confirmed
that the UDP-WA would commence in 2016 [10].
The UDP-WA is coordinated by Genetic Services
WA, which delivers statewide genetics services to all
residents of Western Australia, and is a department
within the North Metropolitan Area Health Service.
The UDP-WA has an initial focus on children. Eligibil-
ity criteria include those who are: (i) generally at least
6 months old; (ii) have chronic, complex and typically
multisystem diseases; (iii) are well known to the public
health system, specifically the children’s hospital and
the multi-disciplinary UDP-WA team of clinicians; (iv)
have typically had multiple specialist assessments and
hospital admissions; and (v) have clinical factors sup-
porting the possibility of obtaining a diagnosis with
current approaches, yet remain undiagnosed (e.g., mul-
tiple affected family members, consanguinity, highly
unique phenotypic combinations, facial dysmorphism,
growth disturbances e.g., short or tall stature, and
microcephaly).
Patients who meet these criteria are reflective of those
with the highest need within the undiagnosed community.
The UDP-WA is being delivered using existing resources
meaning the pace of implementation needs to be manage-
able and cognisant of other work commitments of the
team delivering the program. At this stage, the UDP-WA
admits one patient per month and does not accept exter-
nal referrals.
UDP-WA Team
This team consists of core roles: Program Director,
Program Coordinator, Genetic Counsellor and Expert
Panel. The Program Director oversees the program and
is responsible for its clinical management. The Coordinator
is the point of contact with families and helps to ar-
range appointments for tests and investigations during
the program’s Clinical Stage. Genetic Counselling is
provided to families throughout the program. The
Expert Panel is a multi-disciplinary team made up of
specialists from a range of medical fields. The role of the
Expert Panel is to review existing medical history of pro-
gram patients and make recommendations for further
clinical assessment. The Expert Panel is purposely
composed of a diverse group of physicians, for instance
covering clinical genetics, neurology, imaging, endo-
crinology, gastroenterology, cardiology, haematology,
ophthalmology, respiratory medicine, metabolic medi-
cine and others. All panel members receive patient
summaries and can comment on these. Irrespective of
the clinical domains identified in each patient and given
the typically multisystem presentations, any and all of the
specialists are encouraged to contribute and to attend
panel meetings to provide a diverse range of perspectives
that encourages broad and lateral thinking, and ultimately
for triangulation on diagnostic possibilities.
Clinical flow
To provide structure and a sense of coherence and direc-
tion for the new program, a schematic of a clinical pathway
was developed (see Fig. 1.)
Submission template and distribution of summaries
The NIH has shared copies of protocols used in the im-
plementation of their UDP program and these have been
adapted for local conditions.
The patient submission template is a key summary
document guiding the Expert Panel review of each pa-
tient’s case (see Additional file 1). As highlighted by Tifft
and Adams [1], the cumulative medical record for UDP
patients is often several hundred pages in length and
there is substantial work involved in getting this pre-
pared for review; this has proved no different in the WA
case. The summary is developed by the clinician respon-
sible for identifying the child as a potential UDP partici-
pant (called the referring clinician). The summary
includes text and also photographs of the child and rele-
vant family members. Triaging occurs via the Program
Director, with the opportunity for consultation for con-
sensus with the Expert Panel members.
The Program Director also reviews all available medical
records, including all hard copy records and electronically
available investigations and makes modifications to the
submission template accordingly. The submission tem-
plate is distributed to the Expert Panel 1 week before their
review meeting to allow initial thoughts to be generated
and to allow a forum for broad contribution, including
from those who cannot attend at the specific Expert Panel
meeting relevant to that child.
Presentation of accurate and up to date information in
the submission template, such as the timing of tests and
their results, is critical for a robust informed discussion
of each case and to guide investigations. The submission
template forms the basis for an evolving documentation
of diagnostic suggestions, planned investigations and
their results, diagnosis (when achieved), and suggestions
for further assessments or changes in management.
Patient flow, assessments and investigations
Following the development of the submission template
and selection by the Program Director of patients to par-
ticipate in the program, the UDP-WA is being delivered
to patients in seven key stages.
Stage 1
Parents/caregivers of children are invited to take part in
the program and following their acceptance, they have a
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conversation with the Program Coordinator (a genetic
counsellor) to learn about the program.
Stage 2
The Expert Panel meets to review the case of the program
participant. During this meeting they generate a differen-
tial diagnosis and map out a series of clinical assessments
and investigations they believe will optimise the chance of
achieving a diagnosis.
Stage 3
Patients attend a day facility at the children’s hospital for
up to 5 days where they undertake the range of clinical as-
sessments and investigations set out by the Expert Panel.
On occasion, a diagnosis has been made through stages 1
and 2, thus obviating the need for this stage. Stages 2 and
3 provide the platform for capturing the power of a coor-
dinated effort of a group of multiple experts centered
around one patient at time, in the same place, and at the
same time. This provides the means to realise benefits that
may not be achieved through sequential individual assess-
ments. It also captures nuances that are not necessarily
communicated through written notes.
Stage 4
With the consent of the patient/family, the UDP-WA
Program Director shares de-identified phenotypic and gen-
omic data about the child with national and international
partners to maximise the opportunity for finding a
diagnosis. To enable this, data can be deposited into
the Undiagnosed Diseases Program Integrated Collab-
oration System which is a collaborative workspace for
the UDNI.
Stage 5
The UDP-WA team determines whether a definitive diag-
nosis can be found at this stage.
Stage 6
Parents/caregivers of children in the program attend a
meeting with the Program Director to discuss the
findings.
Stage 7
A report is written for patients that outlines the defini-
tive diagnosis that was achieved (if any), important new
phenotypic findings and test results and suggestions for
further assessments and changes in care, which include
facilitating connections with relevant support groups or
patient communities.
Genomic testing
Genomic analyses are performed in Stage 3 of the progam,
with parallel and complementary approaches. PathWest
Diagnostic Genomics undertakes phenotype-driven in-
silico filtered whole exome sequencing, as described
previously [5]. The Garvan Institute through its clinical
testing arm, Genome One, undertakes whole genome
analysis using Illumina TruSeq DNA library preparation™
on Hamilton automated liquid handling systems, the
Fig. 1 Program Schematic. This schematic represents the Clinical flow of the Undiagnosed Diseases Program WA
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Illumina HiSeq X DNA™ sequencing system and a mixture
of open source and in house data analysis pipeline and
variant filtering [11]. Typically this involves trio analysis of
an affected child and unaffected parents, but this can be
modified depending on the pedigree e.g., if there are
multiple affected family members.
Data sharing
Sharing patient data as part of the UDP-WA is critical
aspect of the program that increases the opportunity of
finding diagnoses for patients, and that allows their
data to potentially help diagnose patients in other juris-
dictions. Data sharing with the UDNI is an evolving
process which involves, in the first instance, a commit-
ment to sharing a minimum set of data including
human phenotype ontology terms and variants in
candidate genes. The UDP-WA has access to the Un-
diagnosed Diseases Program Integrated Collaboration
System (UDPICS) which is a collaborative workspace
for undiagnosed diseases patients. Data can also be
shared via secure online, internationally utilized reposi-
tories such as Phenome Central, which also enables
matchmaking. Matchmaking refers to the process
whereby a patient’s phenotype and/or genotype can be
used to find patients with similar phenotypes and/or
genotypes i.e., matched, to enable a diagnosis to be
found. Presently this is being supported in Western
Australia through the use of the clinical service use of
the knowledge management platform, Patient Archive
(PA). PA is interoperable with matchmaking pathways,
for example it is able to provide data to Phenome
Central. In Japan, sharing data involves the use of the
Patient Archive architecture, under the name Initiative
on Rare and Undiagnosed Diseases (IRUD) exchange.
An interoperable ecosystem of approaches for patients
with Undiagnosed Diseases continues to evolve.
Illustrative cases
Case 1
The first child admitted to the UDP-WA program was
a 7 year old girl with a congenital multisystem disorder.
She had nearly 50 hospital inpatient admissions, 13
general anaesthetics and more than 200 hospital out-
patient visits for consultations across multiple specialist
clinics. She had been presented to national and inter-
national experts, the latter including a virtual inter-
national expert dysmorphology network. Discussions at
the Expert Panel meeting included multiple specialists
suggesting the possibility of various RNA processing
disorders. A literature review by panel members that
evening narrowed the search to Trichohepatoenteric
syndrome, a condition with a prevalence of approximately
1 in 1 million. Subsequently compound heterozygous
SKIV2L mutations were identified by re-analysis of exome
sequencing data. Because of the diagnosis the family has
been referred into the appropriate management pathways,
with the potential to reduce unnecessary and expensive
services, and provides the family and medical system with
increased certainty. It also allowed the family to connect
with other families for support and to reduce isolation.
Case 2
The second child admitted to the UDP-WA program was
an 11 year old girl with a congenital multisystem disorder
associated with short stature, an aesthetic habitus and pro-
geroid facies. Amongst the possibilities discussed by the
Expert Panel was an exon 64 Fibrillin-1 mutation. This
had been considered previously and assessed by mono-
genic sequencing and by in-silico filtered targeted exome.
Following the panel meeting, exome data were reviewed
including with a focus on new candidate diagnoses raised
during the meeting. No mutation was identified. Given
the suggestion by multiple panel members of a marfanoid
condition, and despite a normal echocardiogram 2 years
previously, a repeat echocardiogram was organized during
her admission. This demonstrated aortic root and pul-
monary artery dilatation. Also, a repeat skeletal survey
showed the new finding of acro-osteolysis. No mutation in
known acro-osteloysis-associated genes was detected in
the exomic data. Trio whole genome analysis is pending.
Whilst no definitive diagnosis has yet been confirmed, the
UDP-WA assessment uncovered a highly significant man-
ageable phenotype (aortic dilatation).
Discussion
We have described the conceptualization and implemen-
tation of the Undiagnosed Diseases Program-Western
Australia (UDP-WA). This clinical service program,
offered within a public health system, was developed to
address the unmet needs of those on a protracted diagnos-
tic odyssey. It is a cross-disciplinary initiative targeted to
those with particularly complex multisystem disorders,
with (when required) an inpatient component. It is a
supplement to and synergistic with, an existing out-
patient clinical diagnostic pipeline provided through
one specialty [5].
The UDP-WA has been implemented following a
process of national, regional and international multi-
stakeholder engagement. It is being delivered within a
public health system to: build on existing state-wide
initiatives within that system that facilitate earlier and
more accurate diagnosis; allow engagement of world
standard clinical specialists across multiple disciplines;
integrate with existing clinical flow across the breadth
of specialties involved; and allow for geographically and
financially equitable access to the program by undiag-
nosed patients.
Baynam et al. Orphanet Journal of Rare Diseases  (2017) 12:83 Page 6 of 8
Even at this early stage, the UDP-WA is delivering a
number of key outcomes, namely:
1) Diagnoses including those confirmed on genomic or
phenotypic grounds.
2) There has been refinement of management for
patients with and without a diagnosis, such as that
resulting from the detection of aortic dilatation in
illustrative case 2.
3) Provides a platform for capacity building in
diagnostic approaches, including phenomics and
genomics that concurrently informs and learns from
the multiple specialties that are engaged. This
supports simultaneous and efficient cross-
disciplinary mainstreaming of these approaches.
4) Supports clinical training through the attendance of
junior medical staff. The junior staff have the
opportunity to learn from the individual and
cumulative wisdom of the senior specialists as they
discuss the investigation and management of
extremely high acuity cases.
5) Promotes workforce retention and engagement, with
senior and/or retired clinicians providing the benefit
of their unparalleled wealth of experience.
6) The Expert Panel review meetings allow for
discussions centered around one patient at one time,
in one place. This captures the nuances of clinical
assessments that are not necessarily evident in
written communication.
7) Provides a further pipeline to local, national and
international translational research, and related
training in clinical research.
8) It has fostered the engagement of medical students
in rare and undiagnosed diseases, including
connection to Students4Rare Diseases [12] and is
contributing to the rare diseases knowledge base
through crowdsourced curation of disease data
including, but not limited to, Gene Wiki [13].
A recurrent and predominating theme expressed by
the families participating in the UDP is the psychological
benefit of connectedness. This is particularly the case for
those with a definitive diagnosis who are connected to
the shared experience and support of other families liv-
ing with the same condition. However, it can also be the
case for those who remain undiagnosed given the ex-
panded network of tailored support for Undiagnosed pa-
tients and families through advocacy organisations such
as: Syndromes Without a Name, United Kingdom [14]
and Australia [15]; the “Undiagnosed Diseases Commu-
nity” of Rare Connect [16], EURORDIS; and the Rare
and Undiagnosed Network, National Organisation for
Rare Disorders [17]. This feeling of connectedness also
extends to the staff participating in the program who are
united in purpose through new hope for the patients
and families they serve.
The process of conceptualizing and implementing this
program has drawn media and philanthropic attention
and stimulated new precision medicine research initia-
tives. It has also supported the uptake of the UDP across
other Australian sites. An Australia-New Zealand Un-
diagnosed Diseases Program Executive Committee has
been formed and several jurisdictions are in various
stages of planning or implementing UDP programs. Staff
from Westmead Children’s Hospital and the Garvan In-
stitute of Medical Research recently hosted a workshop
to discuss implementing a UDP in the state of New
South Wales [18] and the Victorian Clinical Genetics
Service has initiated their program.
Planned further work includes the expansion of the
UDP-WA to include adult patients referred to the pro-
gram by members of the Expert Panel. When this be-
comes successful, the program will then progress towards
accepting external referrals from other clinicians. A com-
munity advisory panel will also be established. Addition-
ally, a longitudinal study following parents/caregivers of
children going through the program is currently underway
as are health economic evaluations relating to the UDP-
WA. Plans for a staff impact study, that will include a
critical examination of some of the emerging benefits
mentioned in this paper, are also being explored.
Conclusion
Eight years after the commencement of the NIH UDP in
Bethesda Maryland, a UDP had been established in West-
ern Australia, some 18,000 km away. In this paper we de-
scribe the process of implementing the UDP-WA in a
public health system in the hope that this will assist other
jurisdictions in considering and implementing similar ap-
proaches. The UDP-WA is a complementary approach to
an existing statewide genomic diagnostic pipeline. We pro-
vide some initial results including some foreseen outcomes
such as definitive diagnosis and refined management. Also,
we describe some less readily anticipated important out-
comes including increased staff cohesion, dissemination of
genomic and phenomic knowledge, supporting the training
of junior medical staff, retaining/re-attracting work force
capacity and generating enthusiasm and engagement of
medical students and researchers. The multi-stakeholder
engagement, including, but not limited to, the support and
enthusiasm of clinicians and health system managers in-
volved in delivery of this program has been critical.
Additional file
Additional file 1: Undiagnosed Diseases Program WA Patient Summary
Template. (DOCX 14 kb)
Baynam et al. Orphanet Journal of Rare Diseases  (2017) 12:83 Page 7 of 8
Abbreviations
GSWA: Genetic Services of Western Australia; RUDDS: Rare and Undiagnosed
Diseases Diagnostic Service; UPD: Undiagnosed Diseases Program;
WES: Whole Exome Sequencing
Acknowledgements
We thank all the children and their families who have participated in this
program for their understanding feedback and patience. Also we acknowledge
the support of clinical and non-clinical staff involved. We thank all the clinical
and non-clinical staff at Genetic Services of Western Australia, the Office of
Population Health Genomics, the Western Australian Register of Developmental
Anomalies, Princess Margaret and King Edward Memorial Hospitals. GB thanks
his wife and family for their support.
Funding
GB was supported by the Raine Clinical Research Fellowship.
Availability of data and supporting materials
Data sharing is not applicable to this article as no datasets were generated
or analyzed during the current study.
Authors’ contributions
Clinical phenotyping, manuscript review: GB, NP, FM, ST, JG, CKB, AV, JS, BL,
SK, RP, PH, GP, CP, LS. Program coordination and manuscript review: SB.
Precision phenotyping: LS, RP, SK. Data analysis and manuscript review: KM,
JB, TR. Manuscript review: AZ, TG, MED, JS, SG, CT, DT, PL, BM, JSM, TR, GP,
CP, HW. Service planning, clinical implementation, policy and manuscript
review: JG, GB, TW, AH, CEW, CM, AB, PWO, GC, JC, FD, SJ, AJ, KK, WG, HD. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Consent was obtained from patients for the use of patient data.
Ethics approval and consent to participate
The research components of this platform are performed under approval by
the Princess Margaret Hospital Foundation Ethics Committee.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Genetic Services of Western Australia, Department of Health, Government of
Western Australia, Perth, WA, Australia. 2School of Paediatrics and Child
Health, University of Western Australia, Perth, WA, Australia. 3Institute for
Immunology and Infectious Diseases, Murdoch University, Murdoch, WA,
Australia. 4Office of Population Health Genomics, Public Health Division,
Department of Health, Government of Western Australia, Perth, WA, Australia.
5Telethon Kids Institute, University of Western Australia, Perth, WA, Australia.
6Diagnostic Genomics, PathWest, Department of Health, Government of
Western Australia, Perth, WA, Australia. 7Centre for Population Health
Research, Curtin Health Innovation Research Institute, Curtin University of
Technology, Perth, WA, Australia. 8School of Pathology and Laboratory
Medicine, University of Western Australia, Perth, WA, Australia. 9Centre for
Comparative Genomics, Murdoch University, Perth, WA, Australia. 10Public
Health Division, Department of Health, Government of Western Australia,
Perth, WA, Australia. 11Western Australian Register of Developmental
Anomalies, Perth, WA, Australia. 12King Edward Memorial Hospital, Perth, WA,
Australia. 13School of Spatial Sciences, Curtin University, Perth, WA, Australia.
14Cooperative Research Centre for Spatial Information, Perth, WA, Australia.
15Perth Children’s Hospital, Perth, WA, Australia. 16Kinghorn Centre for Clinical
Genomics, Garvan Institute for Medical Research, Darlinghurst, NSW, Australia.
17St. Vincent’s Clinical School, Faculty of Medicine, University of New South
Wales, Darlinghurst, NSW, Australia. 18The Children’s Hospital at Westmead,
Clinical Genetics Service, Westmead, NSW, Australia. 19National Human
Genome Research Institute, National Institutes of Health, Bethesda, Rockville,
MD, USA. 20Undiagnosed Diseases Program, Common Fund, Office of the
Director, National Institutes of Health, Bethesda, Rockville, MD, USA.
21National Centre for Advancing Translational Sciences, National Institutes of
Health, Bethesda, Maryland, USA. 22Instituto Superiore di Sanità, National
Center for Rare Diseases, Rome, Italy. 23Canadian Institutes of Health
Research, Institute of Genetics, Montreal, Canada. 24Keio University School of
Medicine, Tokyo, Japan. 25Wilhelm Foundation, Brottby, Sweden.
26Department of Medical Genetics, University of Pécs, Pécs, Hungary.
Received: 18 December 2016 Accepted: 26 March 2017
References
1. Tifft CJ, Adams DR. The National Institutes of Health undiagnosed diseases
program. Curr Opin Pediatr. 2014;26(6):626–33.
2. European Organisation for Rare Diseases. Survey of the delay in diagnosis
for 8 rare diseases in Europe (EurordisCare2). EURORDIS. 2007.
3. Molster C, Urwin D, Di Pietro L, Fookes M, Petrie D, van der Laan S, et al.
Survey of healthcare experiences of Australians living with rare diseases.
Orphanet J Rare Dis. 2016;11:30.
4. Taruscio D, Groft SC, Cederroth H, Melegh B, Lasko P, Kosaki K, et al.
Undiagnosed Diseases Network International (UDNI): White paper for global
actions to meet patient needs. Mol Genet Metab. 2015;116(4):223–5.
5. Baynam G, Pachter N, McKenzie F, Townshend S, Slee J, Kiraly-Borri C, et al.
The rare and undiagnosed diseases diagnostic service - application of
massively parallel sequencing in a state-wide clinical service. Orphanet
J Rare Dis. 2016;11(1):77.
6. International Rare Diseases Research Consortium [cited 2016 22/10/2016].
2016 . Available from: http://www.irdirc.org/.
7. Lee H, Deignan JL, Dorrani N, Strom SP, Kantarci S, Quintero-Rivera F, et al.
Clinical exome sequencing for genetic identification of rare Mendelian
disorders. JAMA. 2014;312(18):1880–7.
8. Ales M, Luca L, Marija V, Gorazd R, Karin W, Ana B, et al. Phenotype-driven
gene target definition in clinical genome-wide sequencing data
interpretation. Genet Med. 2016;2016:31.
9. Gahl WA, Wise AL, Ashley EA. The Undiagnosed Diseases Network of the
National Institutes of Health: A National Extension. Jama. 2015;314(17):1797–8.
10. Western Australian Department of Health. Undiagnosed Diseases Program-WA
[cited 2016 22/10/2016]. 2015. Available from: http://ww2.health.wa.gov.au/
News/Media-releases-archives.
11. Genome.One. [cited 2016 22/10/16]. Available from: https://www.genome.one/.
12. Students 4 Rare Diseases [cited 2016 22/10/2016]. Available from: http://
students4rarediseases.org.
13. Gene Wiki [cited 2016 22/10/2016]. Available from: http://sulab.org/
research/crowdbio/gene-wiki/.
14. Syndromes Without a Name - UK. [cited 12th December 2016].
15. Syndromes Without a Name - Australia. [cited 2016 12th December].
Available from: http://swanaus.com.au/.
16. RareConnect. Undiagnosed diseases Community [cited 2016 12th
December]. Available from: https://www.rareconnect.org/en/community/
undiagnosed-diseases.
17. National Organisation for Rare Disorders. Rare and Undiagnosed Network
[cited 2016 12th December]. 2016 . Available from: https://rarediseases.org/
organizations/rare-undiagnosed-network/.
18. Towards an Undiagnosed Diseases Program in New South Wales: The




Baynam et al. Orphanet Journal of Rare Diseases  (2017) 12:83 Page 8 of 8
